NYSE: EW · Medical Devices
Edwards Lifesciences (EW) fair value: undervalued or overvalued?
As of 26 Sep 2026, Faircurve's model values Edwards Lifesciences (EW) at $74.77 a share. The stock last closed at $85.15, which puts the model's fair value 12.2% below the price. On the model's bands that reads as Overvalued.
Revalued . Price is the close of 2 Oct 2026. Edwards Lifesciences Corporation.
Faircurve Insights · 26 Sep 2026
Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring.
Faircurve's model on 26 Sep 2026 found a fair value of $74.77 a share, the midpoint of 2,000 simulations. This was a move of +1.9% from the previous run on 19 Sep 2026, which gave $73.35. The calibrated range over 63 trading days was $62.73 to $91.17, built from the fair value since there is no live options data for the stock, calibrated weekly against realised prices (4,327 past valuations, refreshed 26 Sep 2026). Ranges built this way held the price 60% of the time at this horizon, and the evidence grade was Medium.
The overall quality score was 60 out of 100 against comparable companies. The model compared it with Boston Scientific Corporation (BSX), DexCom, Inc. (DXCM), GE HealthCare Technologies Inc. (GEHC), Stryker Corporation (SYK), Medtronic plc (MDT), Zimmer Biomet Holdings, Inc. (ZBH), Abbott Laboratories (ABT), and Penumbra, Inc. (PEN). The median size of moves around the last 8 earnings reports, ignoring direction, was 3.3%.
Written from the figures on this page for the 26 Sep 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
What price range does the model give EW?
The calibrated range for EW over 63 trading days is $62.73 to $91.17. There is no live options data for this stock, so the range is built from the fair value and calibrated weekly against realised prices (n = 4,327 past valuations, refreshed 26 Sep 2026). Ranges built this way held the price 60% of the time at this horizon.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $63.84 to $86.75. In 21% of the simulations the fair value came out above the price the model ran on.
How does EW score on business quality?
Edwards Lifesciences's overall quality score is 60 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.
| Factor | Score (0 to 100) | Headline measure | Peer median |
|---|---|---|---|
| ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend. | 57 | 14.8%ROIC | 10.1% |
| Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash). | 77 | 1.43xFCF / net income | 1.29x |
| Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analyst estimate revisions. | 75 | 11.5%Revenue growth, trailing | 10.4% |
| Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks. | 29 | 0.9%Net buybacks / market value | 1.6% |
| Balance sheetNet debt to EBITDA and interest coverage. | 100 | -1.43xNet debt / EBITDA | 1.03x |
| StabilityDownside volatility of the EBITDA margin over the last five years. | 0 | 3.7 ptsEBITDA margin downside volatility, 5y | 1.1 pts |
How does EW compare with similar companies?
The companies in medical devices closest to Edwards Lifesciences in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| BSX Boston Scientific Corporation | $42.60 | $46.67 | +9.6% | Fairly valued |
| DXCM DexCom, Inc. | $85.36 | $85.74 | +0.4% | Fairly valued |
| GEHC GE HealthCare Technologies Inc. | $64.29 | $70.99 | +10.4% | Fairly valued |
| SYK Stryker Corporation | $275.43 | $272.42 | -1.1% | Fairly valued |
| MDT Medtronic plc | $86.38 | $80.17 | -7.2% | Fairly valued |
| ZBH Zimmer Biomet Holdings, Inc. | $88.29 | $109.35 | +23.9% | Undervalued |
| ABT Abbott Laboratories | $97.50 | $98.90 | +1.4% | Fairly valued |
| PEN Penumbra, Inc. | $317.55 | $285.08 | -10.2% | Fairly valued |
When does EW report earnings, and how has the stock reacted?
Edwards Lifesciences's next earnings report is scheduled for 29 Oct 2026. Companies can move their dates.
Options prices on 2 Oct 2026 imply a move of about 9.4% in either direction through the nearest expiry, about 48 days out, a window that includes the report. That is the size the market is pricing, not a direction.
How EW moved around its last 8 earnings reports
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across these 8 reports, ignoring direction, was 3.3%.
| Report date | Two session move |
|---|---|
| 23 Jul 2026 | -2.1% |
| 23 Apr 2026 | +3.2% |
| 10 Feb 2026 | +3.3% |
| 30 Oct 2025 | -0.3% |
| 24 Jul 2025 | +4.0% |
| 23 Apr 2025 | +6.4% |
| 11 Feb 2025 | +6.6% |
| 24 Oct 2024 | -1.7% |
Edwards Lifesciences at a glance
Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring.
- Market value
- $49.7B
- Sector
- Healthcare
- Industry
- Medical Devices
- Revenue expected, next twelve months
- $7.3B
- Consensus revenue growth, next fiscal year
- +11.6%
- Analysts with estimates
- 16
- Beta to the US market
- 0.52
- First valued by Faircurve
- 1 May 2026
How the fair value is worked out: the model prices Edwards Lifesciences on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 19 Sep 2026 the model's fair value for EW was $73.35. As of 26 Sep 2026 it is $74.77, a change of +1.9%. The model revalues every stock it covers each week, and again after an earnings report.
Questions about Edwards Lifesciences's valuation
Is Edwards Lifesciences stock undervalued or overvalued?
On Faircurve's model, EW reads as Overvalued as of 26 Sep 2026. The model's fair value is $74.77 a share against a last close of $85.15, a gap of -12.2%.
What is EW's fair value?
$74.77 a share as of 26 Sep 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $63.84 to $86.75.
What price range does the model give EW?
$62.73 to $91.17 over 63 trading days. Ranges built this way held the price 60% of the time across 4,327 past valuations, refreshed 26 Sep 2026.
When does Edwards Lifesciences report earnings next?
The next report is scheduled for 29 Oct 2026. Companies can move their dates.
How much has EW moved on past earnings reports?
Across its last 8 reports the median two session move was 3.3%, ignoring direction. The largest was +6.6% around the report of 11 Feb 2025.
How confident is the model in this valuation?
The model's evidence grade for EW is medium. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.